聚合顺(605166) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,562,641,215.60, a decrease of 4.63% compared to the same period last year[4] - Net profit attributable to shareholders increased by 15.04% to CNY 80,786,922.02, driven by higher product sales[4] - The net profit after deducting non-recurring gains and losses rose by 19.31% to CNY 76,677,215.59, also due to increased sales volume[4] - Basic earnings per share increased by 18.18% to CNY 0.26, reflecting the growth in net profit[4] - The total profit for Q1 2025 was CNY 97,590,572.56, up from CNY 94,263,987.07 in Q1 2024, reflecting a growth of 3.5%[18] - The net profit attributable to the parent company's shareholders for Q1 2025 was CNY 80,786,922.02, an increase of 15.5% compared to CNY 70,224,824.17 in Q1 2024[19] Cash Flow and Liquidity - The cash flow from operating activities turned positive with a net amount of CNY 29,909,876.48, a significant recovery from a negative cash flow in the previous year[4] - The net cash flow from operating activities for Q1 2025 was CNY 29,909,876.48, a significant improvement from a net outflow of CNY 313,508,662.30 in Q1 2024[22] - The total cash and cash equivalents at the end of Q1 2025 were CNY 1,068,649,297.22, compared to CNY 862,916,621.89 at the end of Q1 2024, showing a year-over-year increase of 23.9%[23] - The company reported a decrease in cash and cash equivalents to RMB 2,499,395,254.81 as of March 31, 2025, down from RMB 2,764,636,931.51 at the end of 2024, a decline of about 9.6%[13] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,216,879,237.55, an increase of 1.96% from the previous year[5] - Current assets as of March 31, 2025, totaled RMB 4,292,099,130.43, slightly up from RMB 4,251,557,289.65 at the end of 2024[13] - Non-current assets totaled RMB 1,924,780,107.12 as of March 31, 2025, compared to RMB 1,845,913,863.68 at the end of 2024, indicating a growth of about 4.3%[14] - Total liabilities increased to RMB 4,045,603,046.61 in Q1 2025 from RMB 3,894,162,079.88 in Q4 2024, representing an increase of approximately 3.9%[15] - The company's total assets reached RMB 6,216,879,237.55 as of March 31, 2025, up from RMB 6,097,471,153.33 at the end of 2024, reflecting a growth of about 2.0%[14] Operating Costs and Expenses - Total operating costs for Q1 2025 were RMB 1,483,646,543.66, down 4.8% from RMB 1,558,546,056.52 in Q1 2024[17] - Operating costs specifically decreased from RMB 1,508,399,538.84 in Q1 2024 to RMB 1,435,007,079.45 in Q1 2025, reflecting a reduction of approximately 4.8%[17] - The company reported a decrease in sales expenses to CNY 2,872,227.12 in Q1 2025 from CNY 2,226,687.29 in Q1 2024, reflecting a strategic reduction in costs[18] - Research and development expenses for Q1 2025 were CNY 44,477,629.91, slightly down from CNY 46,693,567.55 in Q1 2024, indicating a focus on cost management[18] - The company incurred financial expenses of CNY -11,288,721.42 in Q1 2025, slightly higher than CNY -11,213,069.55 in Q1 2024, indicating stable financial management[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,120, indicating a stable shareholder base[10] Revenue Trends - Sales revenue from goods and services received in Q1 2025 was CNY 1,123,929,370.42, down from CNY 1,309,937,900.42 in Q1 2024, indicating a decline of 14.2%[22] - The decline in operating revenue was primarily attributed to a significant drop in the price of key raw material caprolactam compared to the previous year[8] Government Support - The company received government subsidies amounting to CNY 5,075,062.16, which positively impacted the financial results[6]